Akari Therapeutics Plc (AKTX) and Leap Therapeutics Inc. (NASDAQ:LPTX) Comparing side by side

This is a contrast between Akari Therapeutics Plc (NASDAQ:AKTX) and Leap Therapeutics Inc. (NASDAQ:LPTX) based on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akari Therapeutics Plc 3 0.00 N/A -1.07 0.00
Leap Therapeutics Inc. 2 0.00 N/A -1.71 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Akari Therapeutics Plc and Leap Therapeutics Inc.


Table 2 has Akari Therapeutics Plc and Leap Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Akari Therapeutics Plc 0.00% -191.7% -104.1%
Leap Therapeutics Inc. 0.00% -210% -77.6%


1.5 and 1.5 are the respective Current Ratio and a Quick Ratio of Akari Therapeutics Plc. Its rival Leap Therapeutics Inc.’s Current and Quick Ratios are 2.7 and 2.7 respectively. Leap Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Akari Therapeutics Plc.

Insider & Institutional Ownership

The shares of both Akari Therapeutics Plc and Leap Therapeutics Inc. are owned by institutional investors at 5.8% and 40.5% respectively. Insiders owned 57.08% of Akari Therapeutics Plc shares. Insiders Comparatively, owned 13.26% of Leap Therapeutics Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akari Therapeutics Plc -10.12% -4.73% 58.95% 63.24% 56.48% 92.36%
Leap Therapeutics Inc. -8.33% -12.5% -1.28% -62.98% -79.3% -23%

For the past year Akari Therapeutics Plc has 92.36% stronger performance while Leap Therapeutics Inc. has -23% weaker performance.


Akari Therapeutics Plc beats Leap Therapeutics Inc. on 4 of the 6 factors.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. Its clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate LeapÂ’s DKK1 antagonist, DKN-01, in combination with MerckÂ’s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.